Impact of gender on outcomes in chronic systolic heart failure

International Journal of Cardiology

Volumn 117, Issue 2, 2007, Pages 214-221

  Ng, Austin Chin Chwan ^a,b   Wong, Helen Siu Ping ^a   Yong, Andy Sze Chiang ^a,b   Sindone, Andrew Paul ^a  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Female; Gender; Heart failure; Male; Outcomes

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE; NITRIC ACID DERIVATIVE; RAMIPRIL; SIMVASTATIN; SPIRONOLACTONE; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHRONIC DISEASE; COMORBIDITY; DISEASE SEVERITY; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC HEART FAILURE;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL ANALYSIS; SYSTOLE; TREATMENT OUTCOME;

EID: 33947373439     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.04.079     Document Type: Article

References (30)

1. American Heart Association. Heart disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, Texas
2. Bonow R.O., Smaha L.A., Smith Jr. S.C., Mensah G.A., and Lenfant C. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106 13 (2002) 1602-1605
3. Swedberg K., Cleland J., Dargie H., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 11 (2005) 1115-1140
4. Field B. Heart failure..what of the future? Australian institute of Health and Welfare. Bulletin vol. 6 (2003), AIHW
5. Roger V.L., Weston S.A., Redfield M.M., et al. Trends in heart failure incidence and survival in a community-based population. JAMA 292 3 (2004) 344-350
6. Gustafsson F., Torp-Pedersen C., Burchardt H., et al. Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure. Eur Heart J 25 2 (2004) 129-135
7. Koelling T.M., Chen R.S., Lubwama R.N., L'Italien G.J., and Eagle K.A. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J 147 1 (2004) 74-78
8. Lee W.Y., Capra A.M., Jensvold N.G., Gurwitz J.H., and Go A.S. Gender and risk of adverse outcomes in heart failure. Am J Cardiol 94 9 (2004) 1147-1152
9. Krum H., and Gilbert R.E. Demographics and concomitant disorders in heart failure. Lancet 362 9378 (2003) 147-158
10. Sheppard R., Behlouli H., Richard H., and Pilote L. Effect of gender on treatment, resource utilization, and outcomes in congestive heart failure in Quebec, Canada. Am J Cardiol 95 8 (2005) 955-959
11. Heer T., Schiele R., Schneider S., et al. Gender differences in acute myocardial infarction in the era of reperfusion (the MITRA registry). Am J Cardiol 89 5 (2002) 511-517
12. Fox K.F., Cowie M.R., Wood D.A., et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 22 3 (2001) 228-236
13. Mathew T.H. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust 183 3 (2005) 138-141
14. The Cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 353 9146 (1999) 9-13
15. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 22 (2001) 1651-1658
16. Rathore S.S., Wang Y., and Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347 18 (2002) 1403-1411
17. Australian Institute of Health and Welfare (AIHW): Heart, stroke and vascular diseases - Australian facts 2004. AIHW 2004; Cat. No. CVD 27: Canberra: AIHW and National Heart Foundation of Australia (Cardiovascular Disease Series No.22).
18. Hellermann J.P., Jacobsen S.J., Gersh B.J., Rodeheffer R.J., Reeder G.S., and Roger V.L. Heart failure after myocardial infarction: a review. Am J Med 113 4 (2002) 324-330
19. Martinez-Selles M., Garcia Robles J.A., Prieto L., et al. Systolic dysfunction is a predictor of long term mortality in men but not in women with heart failure. Eur Heart J 24 22 (2003) 2046-2053
20. Cleland J.G., Goode K., Erhardt L., et al. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). Cardiovasc Drugs Ther 18 2 (2004) 139-152
21. Riedinger M.S., Dracup K.A., Brecht M.L., Padilla G., Sarna L., and Ganz P.A. Quality of life in patients with heart failure: do gender differences exist?. Heart Lung 30 2 (2001) 105-116
22. Bibbins-Domingo K., Lin F., Vittinghoff E., et al. Predictors of heart failure among women with coronary disease. Circulation 110 11 (2004) 1424-1430
23. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41 9 (2003) 1529-1538
24. Lee V.C., Rhew D.C., Dylan M., Badamgarav E., Braunstein G.D., and Weingarten S.R. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 9 (2004) 693-704
25. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 17 (2004) 2618-2626
26. McCullough P.A., Philbin E.F., Spertus J.A., Kaatz S., Sandberg K.R., and Weaver W.D. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39 1 (2002) 60-69
27. Guerra S., Leri A., Wang X., et al. Myocyte death in the failing human heart is gender dependent. Circ Res 85 9 (1999) 856-866
28. Tamura T., Said S., and Gerdes A.M. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 33 2 (1999) 676-680
29. Radin M.J., Holycross B.J., Sharkey L.C., Shiry L., and McCune S.A. Gender modulates activation of renin-angiotensin and endothelin systems in hypertension and heart failure. J Appl Physiol 92 3 (2002) 935-940
30. Mottram P.M., and Marwick T.H. Assessment of diastolic function: what the general cardiologist needs to know. Heart 91 5 (2005) 681-695